HK Stock Market Move | Biocytogen Pharmaceuticals-B (02315) surged over 6% in early trading; its model animal business delivered strong performance in the first half of the year, and the company continues to develop innovative animal models.

Biocytogen Pharmaceuticals-B (02315) surged over 6% in early trading, up 4.64% as of press time, at HK$52.95, with a turnover of HK$9.3465 million. On the news front, in the first half of 2026, Biocytogen Pharmaceuticals-B achieved operating revenue of RMB 941 million, a year-on-year increase of 51.60%; net profit attributable to shareholders of RMB 241 million, a year-on-year increase of 402.29%; and net profit attributable to shareholders after deducting non-recurring items of RMB 197 million, a year-on-year increase of 591.53%. Notably, in the first half of 2026, the company's preclinical products and services business, centered on the sale of innovative animal models, achieved operating revenue of RMB 723 million, a year-on-year increase of 57.94%, with a gross margin of 75.22%. Among this, the model animal business achieved revenue of RMB 446 million, a year-on-year increase of 62.44%, with a gross margin of 82.30%. Western pointed out that Biocytogen Pharmaceuticals-B continues to upgrade the "Thousand Mice, Ten Thousand Antibodies" program. It has completed evaluation and research on approximately 1,200 targets and has basically completed antibody development for all targets, forming a "shelf" of over one million antibody molecule sequences with rich binding epitopes. In May 2026, the company officially launched its next-generation AI-driven antibody discovery platform, RenSuper Workstation, successfully building a triple-driven architecture of "real antibody sequence library + AI + automated intelligent manufacturing platform."